BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sideras K, Bots SJ, Biermann K, Sprengers D, Polak WG, IJzermans JN, de Man RA, Pan Q, Sleijfer S, Bruno MJ, Kwekkeboom J. Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area.Br J Cancer. 2015;112:1911-1920. [PMID: 26057582 DOI: 10.1038/bjc.2015.92] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhou G, Boor PPC, Bruno MJ, Sprengers D, Kwekkeboom J. Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers. Br J Cancer 2021. [PMID: 34400801 DOI: 10.1038/s41416-021-01453-3] [Reference Citation Analysis]
2 Noordam L, Ge Z, Özturk H, Doukas M, Mancham S, Boor PPC, Campos Carrascosa L, Zhou G, van den Bosch TPP, Pan Q, IJzermans JNM, Bruno MJ, Sprengers D, Kwekkeboom J. Expression of Cancer Testis Antigens in Tumor-Adjacent Normal Liver Is Associated with Post-Resection Recurrence of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:2499. [PMID: 34065388 DOI: 10.3390/cancers13102499] [Reference Citation Analysis]
3 Ge Z, Helmijr JCA, Jansen MPHM, Boor PPC, Noordam L, Peppelenbosch M, Kwekkeboom J, Kraan J, Sprengers D. Detection of oncogenic mutations in paired circulating tumor DNA and circulating tumor cells in patients with hepatocellular carcinoma. Transl Oncol 2021;14:101073. [PMID: 33915518 DOI: 10.1016/j.tranon.2021.101073] [Reference Citation Analysis]
4 Roddy H, Meyer T, Roddie C. Novel Cellular Therapies for Hepatocellular Carcinoma. Cancers (Basel) 2022;14:504. [PMID: 35158772 DOI: 10.3390/cancers14030504] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Seifi-Alan M, Shamsi R, Ghafouri-Fard S. Application of cancer-testis antigens in immunotherapy of hepatocellular carcinoma. Immunotherapy 2018;10:411-21. [PMID: 29473472 DOI: 10.2217/imt-2017-0154] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
6 Mucke HA. Patent highlights December 2020-January 2021. Pharm Pat Anal 2021;10:103-10. [PMID: 34003025 DOI: 10.4155/ppa-2021-0005] [Reference Citation Analysis]
7 Grizzi F, Qehajaj D, Chiriva-Internati M, Stifter S. Comment on 'Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area'. Br J Cancer 2016;114:e1. [PMID: 27077695 DOI: 10.1038/bjc.2015.441] [Reference Citation Analysis]
8 Leuchte K, Staib E, Thelen M, Gödel P, Lechner A, Zentis P, Garcia-Marquez M, Waldschmidt D, Datta RR, Wahba R, Wybranski C, Zander T, Quaas A, Drebber U, Stippel DL, Bruns C, von Bergwelt-Baildon M, Wennhold K, Schlößer HA. Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma. Cancer Immunol Immunother 2021;70:893-907. [PMID: 33006650 DOI: 10.1007/s00262-020-02734-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
9 Choi CH, Chung JY, Chung EJ, Sears JD, Lee JW, Bae DS, Hewitt SM. Prognostic significance of annexin A2 and annexin A4 expression in patients with cervical cancer. BMC Cancer 2016;16:448. [PMID: 27402115 DOI: 10.1186/s12885-016-2459-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
10 Cheng Y, Gunasegaran B, Singh HD, Dutertre C, Loh CY, Lim JQ, Crawford JC, Lee HK, Zhang X, Lee B, Becht E, Lim WJ, Yeong J, Chan CY, Chung A, Goh BK, Chow PK, Chan JK, Ginhoux F, Tai D, Chen J, Lim SG, Zhai W, Choo SP, Newell EW. Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021;54:1825-1840.e7. [DOI: 10.1016/j.immuni.2021.06.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Mato JM, Elortza F, Lu SC, Brun V, Paradela A, Corrales FJ. Liver cancer-associated changes to the proteome: what deserves clinical focus? Expert Rev Proteomics 2018;15:749-56. [PMID: 30204005 DOI: 10.1080/14789450.2018.1521277] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Gu X, Mao Y, Shi C, Ye W, Hou N, Xu L, Chen Y, Zhao W. MAGEC2 Correlates With Unfavorable Prognosis And Promotes Tumor Development In HCC Via Epithelial-Mesenchymal Transition. Onco Targets Ther 2019;12:7843-55. [PMID: 31576142 DOI: 10.2147/OTT.S213164] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
13 Rochigneux P, Chanez B, De Rauglaudre B, Mitry E, Chabannon C, Gilabert M. Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials. Cancers (Basel). 2021;13. [PMID: 33450845 DOI: 10.3390/cancers13020271] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
14 Álvarez C, Quiroz A, Benítez-Riquelme D, Riffo E, Castro AF, Pincheira R. SALL Proteins; Common and Antagonistic Roles in Cancer. Cancers (Basel) 2021;13:6292. [PMID: 34944911 DOI: 10.3390/cancers13246292] [Reference Citation Analysis]
15 Zhou G, Sprengers D, Boor PPC, Doukas M, Schutz H, Mancham S, Pedroza-Gonzalez A, Polak WG, de Jonge J, Gaspersz M, Dong H, Thielemans K, Pan Q, IJzermans JNM, Bruno MJ, Kwekkeboom J. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas. Gastroenterology. 2017;153:1107-1119.e10. [PMID: 28648905 DOI: 10.1053/j.gastro.2017.06.017] [Cited by in Crossref: 145] [Cited by in F6Publishing: 161] [Article Influence: 29.0] [Reference Citation Analysis]
16 van Beek AA, Zhou G, Doukas M, Boor PPC, Noordam L, Mancham S, Campos Carrascosa L, van der Heide-Mulder M, Polak WG, Ijzermans JNM, Pan Q, Heirman C, Mahne A, Bucktrout SL, Bruno MJ, Sprengers D, Kwekkeboom J. GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma. Int J Cancer 2019;145:1111-24. [PMID: 30719701 DOI: 10.1002/ijc.32181] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
17 Buonaguro L, Mauriello A, Cavalluzzo B, Petrizzo A, Tagliamonte M. Immunotherapy in hepatocellular carcinoma. Ann Hepatol. 2019;18:291-297. [PMID: 31047849 DOI: 10.1016/j.aohep.2019.04.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 33] [Article Influence: 8.0] [Reference Citation Analysis]
18 Spear TT, Callender GG, Roszkowski JJ, Moxley KM, Simms PE, Foley KC, Murray DC, Scurti GM, Li M, Thomas JT, Langerman A, Garrett-Mayer E, Zhang Y, Nishimura MI. TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors. Cancer Immunol Immunother 2016;65:293-304. [PMID: 26842125 DOI: 10.1007/s00262-016-1800-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
19 Ge Z, Zhou G, Campos Carrascosa L, Gausvik E, Boor PPC, Noordam L, Doukas M, Polak WG, Terkivatan T, Pan Q, Takkenberg RB, Verheij J, Erdmann JI, IJzermans JNM, Peppelenbosch MP, Kraan J, Kwekkeboom J, Sprengers D. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma. Cell Mol Gastroenterol Hepatol 2021;12:443-64. [PMID: 33781741 DOI: 10.1016/j.jcmgh.2021.03.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
20 Mattos ÂZ, Debes JD, Boonstra A, Vogel A, Mattos AA. Immune aspects of hepatocellular carcinoma: From immune markers for early detection to immunotherapy. World J Gastrointest Oncol 2021; 13(9): 1132-1143 [PMID: 34616518 DOI: 10.4251/wjgo.v13.i9.1132] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Heiat M, Hashemi Yeganeh H, Alavian SM, Rezaie E. Immunotoxins Immunotherapy against Hepatocellular Carcinoma: A Promising Prospect. Toxins (Basel) 2021;13:719. [PMID: 34679012 DOI: 10.3390/toxins13100719] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Tauber C, Schultheiss M, Luca R, Buettner N, Llewellyn-Lacey S, Emmerich F, Zehe S, Price DA, Neumann-Haefelin C, Schmitt-Graeff A, Hofmann M, Thimme R. Inefficient induction of circulating TAA-specific CD8+ T-cell responses in hepatocellular carcinoma. Oncotarget. 2019;10:5194-5206. [PMID: 31497249 DOI: 10.18632/oncotarget.27146] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
23 Hofmann M, Tauber C, Hensel N, Thimme R. CD8+ T Cell Responses during HCV Infection and HCC. J Clin Med 2021;10:991. [PMID: 33801203 DOI: 10.3390/jcm10050991] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
24 Jayant K, Habib N, Huang KW, Warwick J, Arasaradnam R. Recent Advances: The Imbalance of Immune Cells and Cytokines in the Pathogenesis of Hepatocellular Carcinoma. Diagnostics (Basel). 2020;10. [PMID: 32466214 DOI: 10.3390/diagnostics10050338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
25 Hendrickson PG, Olson M, Luetkens T, Weston S, Han T, Atanackovic D, Fine GC. The promise of adoptive cellular immunotherapies in hepatocellular carcinoma.Oncoimmunology. 2020;9:1673129. [PMID: 32002284 DOI: 10.1080/2162402X.2019.1673129] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]